NCT04929912 Electroporation for Cancer Treatment Real World Registry
| NCT ID | NCT04929912 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mirai Medical |
| Condition | Skin Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-06-24 |
| Primary Completion | 2026-12-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-06-24 with a primary completion date of 2026-12-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates. The study also aims to characterise side effects and the occurrence of Adverse Events and their relationship to the treatment.
Eligibility Criteria
Inclusion Criteria: * Any patient who has been treated using Calcium Electroporation * Any patient who has been treated using Electrochemotherapy * Patients must be mentally capable of understanding the information given * Patients must give written informed consent. Exclusion Criteria: * None
Contact & Investigator
SEAN H Kinsella
STUDY DIRECTOR
Mirai Medical
Frequently Asked Questions
Who can join the NCT04929912 clinical trial?
This trial is open to participants of all sexes, studying Skin Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04929912 currently recruiting?
Yes, NCT04929912 is actively recruiting participants. Contact the research team at sean@mirai-medical.com for enrollment information.
Where is the NCT04929912 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT04929912 clinical trial?
NCT04929912 is sponsored by Mirai Medical. The principal investigator is SEAN H Kinsella at Mirai Medical. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.